Nyxoah’s (NYXH) Overweight Rating Reaffirmed at Cantor Fitzgerald

Nyxoah (NASDAQ:NYXH)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a report released on Monday,Benzinga reports. They currently have a $11.00 target price on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 257.14% from the company’s current price.

NYXH has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Nyxoah in a report on Monday, December 29th. Stifel Nicolaus reduced their price target on shares of Nyxoah from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.25.

Nyxoah Stock Down 0.3%

NYXH stock opened at $3.08 on Monday. The stock has a fifty day moving average of $4.33 and a 200-day moving average of $4.83. Nyxoah has a fifty-two week low of $3.02 and a fifty-two week high of $11.87. The company has a market capitalization of $119.38 million, a price-to-earnings ratio of -1.15 and a beta of 1.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.16 and a current ratio of 1.25.

Nyxoah (NASDAQ:NYXH) last issued its earnings results on Thursday, March 19th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.03). The business had revenue of $6.62 million for the quarter, compared to the consensus estimate of $5.70 million. Nyxoah had a negative return on equity of 139.18% and a negative net margin of 884.69%. As a group, equities research analysts predict that Nyxoah will post -1.91 earnings per share for the current year.

Institutional Trading of Nyxoah

Several large investors have recently added to or reduced their stakes in NYXH. Raymond James Financial Inc. lifted its position in shares of Nyxoah by 35.6% in the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after purchasing an additional 3,353 shares during the period. Bank of America Corp DE increased its position in shares of Nyxoah by 72.4% during the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after buying an additional 3,303 shares during the period. Citadel Advisors LLC bought a new position in Nyxoah in the third quarter worth about $98,000. Deutsche Bank AG raised its stake in Nyxoah by 40.0% in the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after buying an additional 10,000 shares in the last quarter. Finally, Shay Capital LLC purchased a new stake in Nyxoah in the second quarter worth about $374,000.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.